EpiAxis Therapeutics is a pre-clinical stage company that uses an innovative epigenetics approach which is focused on addressing the critical challenge of overcoming cancer treatment resistance and preventing cancer recurrence.

Our lead drug candidate, epiresatide (METPENZA™), is a promising therapy for difficult to treat cancers. It is an AI-designed synthetic peptide which can restore transcriptional balance and has first-to-market potential as a CoRest Complex disruptor. It is positioned for combination usage with SoC therapies in difficult to treat cancers.

Three indications are being advanced: mucinous adenocarcinoma (MAC) of the colon and rectum, CNS tumours, and triple negative breast cancer (TNBC). These indications all have a very high un-met clinical need, with only marginal improvements observed with current therapeutics approaches.